Patents Assigned to ICAgen
  • Isolated nucleic acids encoding cyclic nucleotide-gated cation channel subunit 3B (CNG3B) polypeptides
    Patent number: 7141419
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of CNG3B, antibodies to CNG3B, methods of detecting CNG3B, and methods of screening for modulators of cyclic nucleotide-gated ion channels using biologically active CNG3B. The invention further provides, in a computer system, a method of screening for mutations of human CNG3B genes as well as a method for identifying a three-dimensional structure of human CNG3B polypeptides.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: November 28, 2006
    Assignee: Icagen, Inc.
    Inventors: Christopher D. Creech, Timothy J. Jegla
  • Bis-benzimidazoles and related compounds as potassium channel modulators
    Patent number: 7132439
    Abstract: The present invention provides a genus of bis-benzimidazole compounds, methods and pharmaceutical compositions that are useful as modulators of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: November 7, 2006
    Assignee: Icagen, Inc.
    Inventors: Xiaodong Wang, Alan B. Fulp, Albert M. van Rhee, Kerry L. Spear
  • CNG2B: a novel human cyclic nucleotide-gated ion channel
    Publication number: 20060240465
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of CNG2B, antibodies to CNG2B, methods of detecting CNG2B, and methods of screening for modulators of cyclic nucleotide-gated ion channels using biologically active CNG2B. The invention further provides, in a computer system, a method of screening for mutations of human CNG2B genes as well as a method for identifying a three-dimensional structure of human CNG2B polypeptides.
    Type: Application
    Filed: May 24, 2006
    Publication date: October 26, 2006
    Applicant: ICAgen, Inc.
    Inventors: Christopher Creech, Timothy Jegla
  • Sulfonamides as potassium channel blockers
    Patent number: 7119112
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: October 10, 2006
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
  • Pyrazolopyrimidine compositions
    Patent number: 7098335
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides pyrazolopyrimidines, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: August 29, 2006
    Assignee: Icagen, Inc.
    Inventors: Robert N. Atkinson, Michael F. Gross, Albert M. van Rhee
  • Imines as ion channel modulators
    Publication number: 20060178346
    Abstract: The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. The active compounds are tri-(aryl or heteroaryl) methane compounds or analogues thereof which further comprise an imine moiety and where the tertiary carbon atom can be replaced with a different atom such as Si, Ge, N or P. The compounds enhance resistance to degradation in a biological medium, inhibit potassium flux in a cell, reduce mammalian cell proliferation, reduce the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 10, 2006
    Applicant: ICAgen, Inc.
    Inventors: Xiaodong Wang, Alan Fulp, Darrick Seconi
  • Human cyclic nucleotide-gated cation channel polypeptide
    Patent number: 7053183
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of CNG2B, antibodies to CNG2B, methods of detecting CNG2B, and methods of screening for modulators of cyclic nucleotide-gated ion channels using biologically active CNG2B. The invention further provides, in a computer system, a method of screening for mutations of human CNG2B genes as well as a method for identifying a three-dimensional structure of human CNG2B polypeptides.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: May 30, 2006
    Assignee: Icagen, Inc.
    Inventors: Christopher D. Creech, Timothy J. Jegla
  • KCNQ5, a novel potassium channel
    Patent number: 7049137
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of KCNQ5, antibodies to KCNQ5, methods of detecting KCNQ5, methods of screening for potassium channel activators and inhibitors using biologically active KCNQ5, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising KCNQ5.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: May 23, 2006
    Assignee: Icagen, Inc.
    Inventor: Timothy J. Jegla
  • SLO2 and SLO4, novel potassium channel proteins from human brain
    Publication number: 20060099640
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.
    Type: Application
    Filed: January 4, 2006
    Publication date: May 11, 2006
    Applicant: ICAGEN, INC.
    Inventors: Timothy Jegla, Julie Witzel
  • DNA encoding Slo2 and Slo4, potassium channel
    Patent number: 7041494
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo2 and Slo4, members of the Slo family of potassium channel proteins, also known as “maxi” or BK potassium channel proteins. Also provided herein are antibodies to Slo2 and Slo 4, methods of detecting Slo2 and Slo 4, methods of screening for potassium channel activators and inhibitors using biologically active Slo2 and Slo 4, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Slo2 and Slo 4.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: May 9, 2006
    Assignee: ICAGEN, Inc.
    Inventors: Timothy James Jegla, Julie Dickson Witzel
  • Sulfonamides as potassium channel blockers
    Publication number: 20060094721
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: August 14, 2003
    Publication date: May 4, 2006
    Applicant: Icagen, Inc.
    Inventors: Grant McNaughton-Smith, Aimee Reed, Robert Atkinson
  • Small and intermediate conductance, calcium-activated potassium channels and uses thereof
    Patent number: 7026451
    Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositons for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: April 11, 2006
    Assignees: Icagen, Incorporated, Oregon Health Sciences University
    Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
  • Heterocyclo inhibitors of potassium channel function
    Patent number: 7005436
    Abstract: Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: February 28, 2006
    Assignees: Bristol Myers Squibb Company, Icagen, Inc.
    Inventors: John Lloyd, Yoon T. Jeon, Heather Finlay, Lin Yan, Michael F. Gross, Serge Beaudoin
  • BK beta subunits of Slo family potassium channels
    Patent number: 6994968
    Abstract: The invention provides isolated nucleic acid and amino sequences of BK beta 2, BK beta 3, and BK beta 4, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo family potassium channels comprising BK beta subunits.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: February 7, 2006
    Assignee: Icagen, Inc.
    Inventors: Timothy James Jegla, Alan Wickenden, Yi Liu
  • Benzanilides as potassium channel openers
    Patent number: 6989398
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: January 24, 2006
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Small conductance, calcium-activated potassium channels (SK 3)
    Patent number: 6987169
    Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: January 17, 2006
    Assignees: Oregon Health Sciences University, Icagen, Inc.
    Inventors: John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
  • BK beta subunits of Slo family potassium channels
    Publication number: 20060004187
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of BK beta 2, BK beta 3, and BK beta 4, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo potassium channels comprising BK beta subunits, and kits for screening for activators and inhibitors of the Slo family potassium channels comprising BK beta subunits.
    Type: Application
    Filed: September 2, 2005
    Publication date: January 5, 2006
    Applicant: ICAGEN, INC.
    Inventors: Timothy Jegla, Alan Wickenden, Yi Liu
  • Sulfone-containing prodrugs
    Publication number: 20050267032
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: May 23, 2005
    Publication date: December 1, 2005
    Applicant: Icagen, Inc.
    Inventors: Alan Fulp, Grant McNaughton-Smith, Aimee Reed, Xiadong Wang
  • Polycyclic pyrimidines as potassium ion channel modulators
    Publication number: 20050267089
    Abstract: The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.
    Type: Application
    Filed: April 13, 2005
    Publication date: December 1, 2005
    Applicants: ICAgen, Inc., Astellas Pharma Inc.
    Inventors: Xiaodong Wang, Kerry Spear, Alan Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo
  • Polycyclic pyrazines as potassium ion channel modulators
    Publication number: 20050239800
    Abstract: The present invention provides a genus of polycyclic pyrazines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.
    Type: Application
    Filed: April 13, 2005
    Publication date: October 27, 2005
    Applicants: ICAgen, Inc., Astellas Pharma Inc.
    Inventors: Xiaodong Wang, Kerry Spear, Alan Fulp, Darrick Seconi, Takeshi Suzuki, Takahiro Ishii, Ayako Moritomo